Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial

RCT (n=557) found atabecestat was associated with dose-related cognitive worsening vs placebo as early as 3 months after starting. There were also neuropsychiatric treatment-emergent adverse effects which appeared to reverse after 6 months off treatment.

JAMA Neurology